Drug firm Zydus Cadila on Tuesday said it has received approval from the US health regulator to market generic Fluocinonide cream used for treatment of various skin conditions.
The final approval from the United States Food and Drug Administration (USFDA) is to market Fluocinonide cream USP, 0.1 per cent, Zydus Cadila said in a statement.
The drug will be manufactured at the group's topical manufacturing facility at Ahmedabad, it added.
It is used to treat a variety of skin conditions such as psoriasis, eczema, dermatitis, allergies and rash, Zydus Cadila said.
The group now has 279 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)